?? Belite Bio to participate in the Leerink Partners Global Healthcare Conference. The company will host a fireside chat on March 10th, 3:00 PM ET available through webcast (signup below). #Fireside #Conference #Webcast Webcast: https://lnkd.in/g7hkWDCy
关于我们
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
- 网站
-
https://www.belitebio.com
Belite Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 上市公司
- 创立
- 2018
- 领域
- RBP4、Drug Development、Dry Age-Related Macular Degeneration、Stargardt Disease、Diabetes、NASH和NAFLD
地点
-
主要
获取路线
5820 Oberlin Drive, Suite 101
US，California，San Diego，92121
Belite Bio员工
动态
-
?? NEWS: Belite Bio (????Nasdaq: BLTE) announces interim analysis results from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent Stargardt Disease subjects. #Tinlarebant #Dragon #Phase3 #Results Read more: https://lnkd.in/eD7WtRrJ
-
-
?? Belite Bio (????Nasdaq: BLTE) is thrilled to be in San Francisco this week, connecting with investors and showcasing our efforts to develop innovative therapies for degenerative retinal diseases with critical unmet medical needs. #JPM2025
-
-
"And God said, 'Let there be light,' and there was light." ?? If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope. ?? In an interview for Vital Signs, produced by Onyx and now available to read in Fortune magazine, Dr. Tom Lin - Founder, Chairman and CEO of Belite Bio - told me about Tinlarebant, a pill in phase 3 clinical trials that modulates the delivery of vitamin A to the eye, reducing the buildup of toxic metabolites to preserve vision. ?? There's huge potential here - lots of new ophthalmology therapeutics might see FDA approvals in 2025, but most treatments for retinal disease involve injections. Belite are offering a pill, the most-sought after modality - read more here: https://lnkd.in/eKkbpuGg
-
-
??BELITE BIO NEWS: Our Founder and CEO Dr. Tom Lin has been featured in Fortune Magazine, offering insights into the groundbreaking capabilities of Tinlarebant. #Fortune #BeliteBio #CEO #Tinlarebant Read the article produced by Onyx, published in Fortune: https://lnkd.in/g92PsuJE
-
-
??Belite Bio (????Nasdaq: BLTE) will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update for Q3 ended September 30, 2024. #BeliteBio #Q3 #Webcast Join the Webcast: https://lnkd.in/gF5W4HEX
-
-
?? BIG congratulations to our Chief Medical Officer, Hendrik P. N. Scholl, MD, for being awarded The Paul Kayser International Award in Retina Research. Read more: https://lnkd.in/gtxdevMW
-
-
??NEW EVENT: Belite Bio (????Nasdaq: BLTE) will present data from its completed Phase II adolescent Stargardt disease trial at the American Academy of Ophthalmology Annual Meeting (AAO 2024) Saturday, October 19, 2024; 10:33 AM – 10:40 AM CDT ??More Info: https://lnkd.in/gJVRAdh3
-
-
??NEW EVENT: Belite Bio (????Nasdaq: BLTE) will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET. ??SIGN UP NOW: https://lnkd.in/e_5buqAg
-